Lymphoma News

Several clinicians will be honored at this year’s Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for Feb. 15-19 in Orlando.

The FDA granted accelerated approval to pirtobrutinib for treatment of certain patients with advanced mantle cell lymphoma.

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

NEW ORLEANS — Patients older than 80 years of age with diffuse large B-cell lymphoma more than tripled their overall survival when receiving at least six cycles of chemotherapy.

Patients treated in integrated cancer centers had higher use of palliative care but overall use remained low, according to a presentation at ASH Annual Meeting and Exposition. Privately insured individuals also showed low utilization.

A blood test may predict which patients are predisposed to developing treatment-related neurotoxicity after chimeric antigen receptor T-cell therapy infusion, according to researchers.

NEW ORLEANS — Since war started in Ukraine, tertiary care centers focused on treating cancers saw a 56% decline in patients with lymphoma, a presenter said.

The risk for suicide remains elevated among individuals diagnosed with cancer compared with the general population, despite a downward trend over the last 2 decades, a recent study found.

The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

NEW ORLEANS — Looking at 185 countries, a projection presented at the ASH Annual Meeting and Exhibition suggests the global burden of non-Hodgkin lymphoma will increase by 778,000 cases by 2040.